Corporate / M&A

IP / IT

Technology and Digital Economy

Competition

Regulatory

Temenos

Homburger News

Share-Image Teamplate Deals-and-Cases

On February 6, 2025, Temenos announced that it has reached an agreement with Montagu Private Equity for the sale of Multifonds, its fund administration software business, for a total Enterprise Value of around USD 400 m including an earn-out. Multifonds is a leading global provider of fund administration software, serving all asset classes across multiple jurisdictions and helping fund administrators, asset managers, insurance companies and pension funds achieve increased operational efficiency, whilst reducing risk.
The Homburger team is led by Dieter Gericke and Daniel Häusermann (both Corporate / M&amp;A) and included Nicola Togni, Romain Hondius, Thomas Romelli, Luca Ellenberger and Miriam Oelgarth (all Corporate / M&amp;A), Gregor Bühler, Philippe Baumann and Kristina Martinovic (all IP / IT, Technology and Digital Economy), Stefan Oesterhelt, Laetitia Fracheboud and Juliette Buob (all Tax) as well as Richard Stäuber and Christoph Grüninger (both Competition, Regulatory).

Homburger advises Temenos on the sale of Multifonds to Montagu Private Equity

Healthcare / Life Sciences

Noema Pharma

On December 11, 2024, Noema Pharma AG announced that it has successfully closed a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised in the round to CHF 130 m (approx. USD 147 m). With its investment in Noema Pharma, EQT Life Sciences joins the syndicate of previous Series B investors including Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.
Noema Pharma is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The new financing will support Noema Pharma&#8217;s four active Phase 2 trials, with key data readouts anticipated in 2025.
Homburger AG advised Noema Pharma AG as transaction counsel in this Series B extension financing round. The Homburger team comprised Andreas Müller, Thierry Burckhardt, Thomas Romelli and Rebecca Sigrist (all Corporate / M&amp;A; Healthcare / Life Sciences), Luca Dal Molin (IP / IT; Healthcare / Life Sciences) as well as Stefan Oesterhelt and Laetitia Fracheboud (Tax).

Homburger advised Noema Pharma AG on its Series B extension financing round

Capital Markets

Financing and Investment Products

Meyer Burger

Homburger News 

On April 3, 2024, Meyer Burger Technology AG (SIX: MBTN) announced the successful completion of its rights offering, raising gross proceeds of CHF 206.75 m. Shares not subscribed by shareholders were placed with institutional investors at the prevailing market price.
Homburger acted as legal and tax counsel to Meyer Burger in this transaction. The Homburger team was co-led by Dieter Gericke and Daniel Häusermann (both Corporate / M&amp;A, Capital Markets) and included Lorenzo Togni (Capital Markets), Jasmin Künzle, Magda Aref, Hans Glent Abildgaard, Thomas Romelli, Cédric Berger, Oliver Dalla Palma, Daniel Wenzinger and Alexander Giger (all Corporate / M&amp;A, Capital Markets), Miguel Sogo and Oliver Mrose (both Corporate / M&amp;A), Eduard De Zordi and Daniel Hulmann (both Financing and Investment Products) as well as Stefan Oesterhelt (Tax).

Thomas
Romelli

Homburger advises Temenos on the sale of Multifonds to Montagu Private Equity

Homburger advised Noema Pharma AG on its Series B extension financing round

Homburger advised Meyer Burger on its CHF 206.75 m rights offering

Join the Team

Thomas Romelli

Career

Languages

Bar Registration

Teams

ThomasRomelli

Homburger advises Temenos on the sale of Multifonds to Montagu Private Equity

Homburger advised Noema Pharma AG on its Series B extension financing round

Homburger advised Meyer Burger on its CHF 206.75 m rights offering

Join the Team

Thomas Romelli

Career

Languages

Bar Registration

Teams

Thomas
Romelli